China Shineway Pharmaceutical Group Ltd (2877.HK) stock: key figures, P/E, revenue and dividend

Health Care · China · ISIN KYG2110P1000

Price
6.41 HKD
Market cap
4.84 bn HKD
P/E (2025)
4.76
P/S (2025)
1.54
Dividend yield
32.20 %
Net margin
30.30 %
Return on equity (ROE)
11.78 %
Return on assets (ROA)
8.81 %

China Shineway Pharmaceutical Group Ltd financials

Fiscal year20242025
Revenue3.78 bn CNY3.14 bn CNY
Gross profit3.04 bn CNY2.42 bn CNY
EBIT903.50 m CNY729.01 m CNY
Net income840.05 m CNY949.95 m CNY
Diluted EPS – continuing operations1.19 CNY1.35 CNY

Full history since 2001, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About China Shineway Pharmaceutical Group Ltd

China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese pharmaceutical products in the People's Republic of China and Hong Kong. The company offers Chinese medicines in the form of injection, soft capsules, and granules; and other dosage forms, including pills and tablets; and traditional Chinese medicine granules in various therapeutic areas, including respiratory system disease, nervous system, digestive system disease, cardiovascular and cerebrovascular, orthopedics, pediatrics, chronic illnesses, and other areas, as well as medication for strengthening the body. It is also involved in the trading of agricultural products. The company was incorporated in 2002 and is headquartered in Shijiazhuang, China. China Shineway Pharmaceutical Group Limited operates as a subsidiary of Forway Investment Limited.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.